NASH pipeline highlights from 2019

Excitement has peaked this year for potential nonalcoholic steatohepatitis therapies as many more studies have revealed positive outcomes in either resolution of nonalcoholic steatohepatitis without worsening of fibrosis or reduction in fibrosis stage without worsening of nonalcoholic steatohepatitis.Healio Gastroenterology and Liver Disease presents 7 reports from this year on the progressive NASH drug pipeline including therapies that have shown promise in tackling NASH and fibrosis directly along with candidates that may provide other important hepatic improvements in liver enzymes andRead More

Share on facebook
Share on twitter
Share on linkedin